SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Interest Coverage Ratio data on file, last reported at 0.73 in Q1 2026.

• Quarterly Interest Coverage Ratio rose 98.24% year-over-year to 0.73 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.11 (up 98.7% YoY) and the FY2025 annual result came in at 1.88, up 94.81% from the prior year.
• Interest Coverage Ratio improved to 0.73 in Q1 2026, from 253.01 in the prior quarter.
• In the past five years, Interest Coverage Ratio ranged from a high of 33.58 in Q4 2024 to a low of 253.01 in Q4 2025.
• A 5-year average of 45.92 and a median of 21.57 in 2022 frame the typical range for Interest Coverage Ratio.
• Annual changes were most pronounced in 2023 — Interest Coverage Ratio sank 2062.85% — and 2024, when it jumped 113.86%.
• Tracing SABS's Interest Coverage Ratio over 5 years: stood at 12.35 in 2022, then slumped by 2062.85% to 242.35 in 2023, then jumped by 113.86% to 33.58 in 2024, then plunged by 853.41% to 253.01 in 2025, then jumped by 99.71% to 0.73 in 2026.
• The last three Interest Coverage Ratio figures came in at 0.73 (Q1 2026), 253.01 (Q4 2025), and 17.4 (Q3 2025), per Business Quant data.